Clinical Trial: A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc)

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07854483) titled 'A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc)' on Sept. 27.

Brief Summary: This Phase 1b, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in participants with refractory Systemic Sclerosis (SSc) who are not responding to standard therapy. Approximately 6-12 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of C-CAR168. Participants will be followed for 24 months (2 years) to evaluate safety, CAR ...